Thursday, May 15, 2014
Publication and contact
Forssman disaccharide antibodies predict positive response to ProstVac-VF
prostate cancer vaccine
Patient sample studies
suggest serum antibodies against Forssman disaccharide could help predict a
positive response to ProstVac-VF, a poxvirus-based cancer vaccine that
induces responses to prostate-specific antigen (KLK3;
as well as a poxvirus-specific carbohydrate called Forssman disaccharide. In
two independent cohorts of over 100 patients, ProstVac-VF-treated patients
who had high Forssman disaccharide serum antibodies showed increased overall
survival compared with those who had low serum antibody levels and those who
received a control vector. In an additional cohort of 13 patients receiving
both ProstVac-VF and the radiopharmaceutical Quadramet,
seven patients had high levels of Forssman disaccharide serum antibodies and
increased overall survival compared with those who had low serum levels of
the antibodies. Next steps could include validating the marker in additional
Bavarian Nordic A/S
has ProstVac-VF rilimogene galvacirepvec in
Phase III testing to treat prostate cancer.
Jazz Pharmaceuticals plc
markets Quadramet samarium 153 lexidronam to treat bone
pain associated with cancer.
Published online May 15, 2014
Patent and licensing status
Campbell, C.T. et al.
Proc. Natl. Acad. Sci. USA; published online
April 14, 2014;
Contact: Jeffrey C. Gildersleeve,
National Cancer Institute,
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]